Tranexamic acid-d₂-1 

Tranexamic acid-d₂-1 is the deuterium labeled Tranexamic acid[1]. Tranexamic acid (Transamin) is an antifibrinolytic for blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments with IC50 of 5 mM[2][3].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

159.22

C₈H₁₃D₂NO₂

2714435-89-7

Solid

White to off-white

OC([C@@H]1CC[C@H](CC1)C([2H])([2H])N)=O

Room temperature in continental US; may vary elsewhere.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  [Content Brief]

  [2]. Bhat A, et al. Tranexamic acid overdosage-induced generalized seizure in renal failure. Saudi J Kidney Dis Transpl. 2014 Jan-Feb;25(1):130-2.  [Content Brief]

  [3]. Couturier R, et al. Continuous or discontinuous tranexamic acid effectively inhibits fibrinolysis in children undergoing cardiac surgery with cardiopulmonary bypass. Blood Coagul Fibrinolysis. 2014 Jan 13.  [Content Brief]